Keystone Symposia – MRT-6160, a highly selective and first-in-class VAV1-directed molecular glue degrader, demonstrates activity in multiple immune-mediated disease models

Monte Rosa Therapeutics Inc. published this content on January 22, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on January 22, 2026 at 15:01 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]